Non-nucleoside reverse transcriptase inhibitorsCompounds of Formula I are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R, R, R, R, R, ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Formula i compound or pharmaceutically acceptable salt thereof:wherein:v is c (r 10), c (o), n (r 11), n or n oxide compound; w is c (r 3), c (o), n (r 12), n or n oxide compound; y is c or n; and z is c or n, and condition is: be no more than two in the middle of v, w, y and the z and contain n;x is o, s, s (o), s (o) 2, n (r a), c (r a) (r b) or c (o); r 1be arya or heta; r 2, r 3and r 10be independently selected from respectively: (1)h，(2) halogen,(3)cn，(4)no 2， (5)c(o)r a， (6)c(o)or a， (7)c(o)n(r a)r b， (8)sr a， (9)s(o)r a， (10)s(o) 2r a， (11)s(o) 2n(r a)r b， (12)n(r a)r b， (13)n(r a)s(o) 2r b， (14)n(r a)c(o)r b， (15)n(r a)c(o)or b， (16)n(r a)s(o) 2n(r a)r b， (17)oc(o)n(r a)r b， (18)n(r a)c(o)n(r a)r b， (19) c 1-6alkyl, (20) c 1-6haloalkyl, (21) c 2-6alkenyl, (22) c 2-6alkynyl, (23)oh，(24) o-c 1-6alkyl, (25) o-c 1-6alkyl, wherein said alkyl is by or aor n (r a) r breplace, (26) o-c 1-6haloalkyl, (27) c 1-6alkyl, described alkyl is replaced by 1-3 substituting group, and each described substituting group is halogen (condition is that alkyl is further replaced by at least one non-halogen group), oh, o-c independently 1-6alkyl, o-c 1-6haloalkyl, cn, no 2, n (r a) r b, c (o) n (r a) r b, c (o) r a, co 2r a, sr a, s (o) r a, s (o) 2r a, s (o) 2n (r a) r b, n (r a) c (o) r b, n (r a) co 2r b, n (r a) s (o) 2r b, n (r a) s (o) 2n (r a) r b, oc (o) n (r a) r bor n (r a) c (o) n (r a) r b, (28)cyce，(29)o-cyce，(30)c(o)o-cyce，(31) c (o) n (r a)-cyce and (32)n(r a)-cyce； r 11and r 12be independently selected from h respectively, halogen, c 1-6alkyl and cyce; ring a is the first ring of unsaturated 6-, wherein represent that this ring contains at least two two keys; ring b and ring a condense, and shared atom y and z with ring a form the saturated or unsaturated ring of 4-7 unit, described ring is chosen wantonly and is contained 1-3 heteroatoms, described heteroatoms is n, o or s independently, wherein when any or two among y and the z are n, the whole heteroatomss of ring among the b comprise any or two among y and the z, and wherein each s is optional is s (o) or s (o) 2, and each n optional be the n-oxide compound, and wherein have 0-2 ring carbon to choose wantonly to be replaced by the oxo base; r 4and r 5be independently selected from respectively: (1)h，(2) c 1-6alkyl, (3) c 1-6alkyl, described alkyl is replaced by following groups: oh, o-c 1-6alkyl, o-c 1-6haloalkyl, cn, no 2, n (r a) r b, c (o) n (r a) r b, c (o) r a, co 2r a, sr a, s (o) r a, s (o) 2r a, s (o) 2n (r a) r b, n (r a) c (o) r b, n (r a) co 2r b, n (r a) s (o) 2r b, n (r a) s (o) 2n (r a) r b, oc (o) n (r a) r b, n (r a) c (o) n (r a) r bor n (r a) c (o) c (o) n (r a) r b, (4) o-c 1-6alkyl, (5) c 1-6haloalkyl, (6) o-c 1-6haloalkyl, (7)oh，(8) halogen,(9)cn，(10)no 2， (11)c(o)n(r a)r b， (12)c(o)r a， (13) c (o)-c 1-6haloalkyl, (14)c(o)or a， (15)sr a， (16)s(o)r a， (17)s(o) 2r a， (18)s(o) 2n(r a)r b， (19)n(r a)r b， (20)n(r a)s(o) 2r b， (21)n(r a)c(o)r b， (22)n(r a)c(o)or b， (23)n(r a)s(o) 2n(r a)r b， (24) oc (o) n (r a) r band (25)n(r a)c(o)n(r a)r b； j equals 0 or 1 integer;k equals 0 or 1 integer;r 6be connected among the b on the annular atoms, this annular atoms is adjacent with shared atom z, and perhaps the annular atoms with adjacent with z is adjacent, and r 6be: (1) wherein each ring n is optional is the n-oxide compound, (2)*-ch 2c(o)n(r a)-aryb， (3)*-ch 2c(o)n(r a)-hetb， (4) *-ch 2c (o) n (r a)-c 1-3alkylidene group-aryb, (5) *-ch 2c (o) n (r a)-c 1-3alkylidene group-hetb, (6) *-ch 2c (o) o-c 1-3alkylidene group-aryb, (7) *-ch 2c (o) o-c 1-3alkylidene group-hetb, (8)*-ch 2-hetb， (9)*-ch 2c(o)-hetb， (10) *-ch 2c (o)-hetc, or (11)*-ch 2ch 2oh； wherein the point that is connected with the compound rest part represented in asterisk;r 7and r 8be independently selected from respectively: (1)h，(2)oh，(3) halogen,(4)cn，(5)no 2， (6) c 1-6alkyl, (7) c 1-6alkyl, described alkyl is replaced by following groups: oh, o-c 1-6alkyl, o-c 1-6haloalkyl, cn, no 2, n (r a) r b, c (o) n (r a) r b, c (o) r a, co 2r a, sr a, s (o) r a, s (o) 2r a, s (o) 2n (r a) r b, n (r a) c (o) r b, n (r a) co 2r b, n (r a) s (o) 2r b, n (r a) s (o) 2n (r a) r b, oc (o) n (r a) r b, n (r a) c (o) n (r a) r bor n (r a) c (o) c (o) n (r a) r b, (8) o-c 1-6alkyl, (9) o-c 1-6alkyl, wherein said alkyl is replaced by following groups: o-c 1-6alkyl, n (r a) r b, c (o) n (r a) r b, c (o) r aor co 2r a, (10) c 1-6haloalkyl, (11) o-c 1-6haloalkyl, (12)n(r c)r d， (13) n (r a)-c 1-6alkylidene group-n (r c) r d, (14)c(o)n(r a)r b， (15)c(o)r a， (16) c (o)-c 1-6haloalkyl, (17)c(o)or a， (18)sr a， (19)s(o)r a， (20)s(o) 2r a， (21)s(o) 2n(r a)r b， (22)cyce，(23)o-cyce，(24)c(o)o-cyce，(25)c(o)n(r a)-cyce， (26)n(r a)-cyce， (27) c that is replaced by cyce 1-6alkyl, (28) by n (r athe o-c that)-cyce replaces 1-6alkyl, (29) o-c that is replaced by c (o)-cyce 1-6alkyl, (30)hete，(31)n(r a)s(o) 2r b， (32) n (r a) c (o) r band (33)n(r a)c(o)n(r a)r b； r 9be h or c 1-6alkyl; each r abe h, c independently ...
비-뉴클레오사이드 역전사효소 억제제 Q, R2, R3, R6, T1, T2, 및 T3이 본원에 정의된 HIV 역전사효소 억제제인 화학식 I의 화합물. 화학식 I의 화합물 및 이의 약제학적으로 허용되는 염 및 이의 전구약물은 HIV 역전사효소의 억제, HIV에 의한 감염의 예방 및 치료 및 AIDS의 예방, 발병 또는 진행의 지연 및 치료에 유용하다. 당해 화합물 및 이의 염은 임의로 기타 항바이러스제, 면역조절제, 항생제 또는 백신과 배합하여 약제학적 조성물의 성분으로서 사용될 수 있다. 화학식 I 화학식 I의 화합물 또는 이의 약제학적으로 허용되는 염. 화학식 I [이미지] 상기 화학식 I에서, Tl 및 T2 및 T3은 서로 독립적으로 H, C1-4 알킬, 할로겐, CN, CH=CH-CN, C(O)RA 또는 (CH2)1-2N(RA)RB이고; R2 및 R3은 서로 독립적으로 (1)H, (2)할로겐, (3)C(O)N(RA)RB, (4)C1-4알킬, (5)CF3, (6)O-C1-4알킬 및 (7)OCF3로 이루어진 그룹으로부터 선택되고; R6은 [이미지], [이미지] [이미지], 또는 (10) -CH2CH2OH이고; J1 및 J2는 서로 독립적으로 H, 할로겐, CN, NO2, Cl-4알킬, CF3, OH, O-C1-4알킬, OCF3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA 또는 S02N(RA)RB이고; J3은 H, 할로겐, CN, C1-4알킬, OH, 옥소, O-C1-4알킬, CF3, OCF3, C(O)NH2, C(O)N(H)CH3, C(O)N(RA)RB, C(O)RA, CO2RA, SO2RA 또는 SO2N(RA)RB이고; L은 N 또는 N 옥사이드이고; Q는 (1) -CH(R4)-, (2) -C(R4)=C(R5)-, (3) -CH(R4)-CH(R5)-, (4) -C(R4)=C(R5)-CH2-, (5) -CH(R4)-CH(R5)-CH2-, (6) -C(R4)=C(R5)-CH=CH-, (7) -CH(R4)-CH(R5)-CH=CH-, (8) -C(R4)=C(R5)-CH2CH2-, (9) -CH(R4)-CH(R5)-CH2CH2-, (10) -C(R4)=N-, (11) -N=C(R4)-, 또는 (12) -N=N-이고; 여기서, Q의 가장 왼쪽 원자는 융합된 벤조에 직접 결합되고; R4 및 R5는 서로 독립적으로 (1) H, (2) C1-4알킬, (3) O-C1-4알킬, (4) CF3, (5) OCF3, 및 (6) 할로겐 으로 이루어진 그룹으로부터 선택되고; R7 및 R8은 서로 독립적으로 (1) H, (2) OH, (3) 할로겐, (4) CN, (5) NO2, (6) C1-4알킬, (7) O-C1-4알킬, (8) O(CH2)2-3N(RA)RB, (9) 0(CH2)1-3C(O)RA, (10) CF3, (11) OCF3, (12) O(CH2)l-2CF3, (12) N(RC)RD, (13) N(RA)-(CH2)2-3-N(RC)RD, 및 (14) C(0)N(RA)RB 으로 이루어진 그룹으로부터 선택되고; 각각의 RA는 독립적으로 H 또는 C1-4알킬이고; 각각의 RB는 독립적으로 H 또는 C1-4알킬이고; 각각의 RC는 독립적으로 H 또는 C1-4알킬이고; 각각의 RD는 독립적으로 H 또는 C1-4알킬이고; 대안적이고 독립적으로 RC와 RD의 쌍 각각은 이들 둘 다가 결합되어 있는 N 원자와 함께 [이미지] 및 [이미지]으로 이루어진 그룹으로부터 선택된 포화된 모노사이클릭 환을 형성하고; (A) Q가 -N=C(R4)-이고 R4가 H가 아닌 경우, R6은 [이미지]가 아니다.